Univariate and multivariate Cox regression analysis of OS in AML-05 trial
| OS . | . | . | Univariate analysis . | Multivariate analysis . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of deaths/patients . | . | . | 95% CI . | . | . | 95% CI . | ||||
| Negative . | Positive . | HR . | P . | Lower . | Upper . | HR . | P . | Lower . | Upper . | |
| CBFB-MYH11 | 93/338 | 1/31 | 0.11 | .03 | 0.02 | 0.80 | 0.08 | .01 | 0.01 | 0.58 |
| Biallelic CEBPA | 93/346 | 1/23 | 0.16 | .07 | 0.02 | 1.13 | 0.10 | .02 | 0.01 | 0.69 |
| RUNX1-RUNX1T1 | 86/263 | 8/106 | 0.19 | <.001 | 0.09 | 0.39 | 0.17 | <.001 | 0.08 | 0.35 |
| NPM1 | 93/351 | 1/18 | 0.19 | .10 | 0.03 | 1.35 | 0.09 | .02 | 0.01 | 0.64 |
| KIT | 80/283 | 14/86 | 0.43 | .02 | 0.21 | 0.85 | ||||
| KMT2A rearrangement | 75/308 | 19/61 | 1.10 | .73 | 0.64 | 1.88 | ||||
| PICALM-MLLT10 | 93/366 | 1/3 | 1.22 | .84 | 0.17 | 8.78 | ||||
| WT1 | 86/345 | 8/24 | 1.33 | .44 | 0.64 | 2.74 | ||||
| KAT6A-CREBBP | 93/366 | 1/3 | 1.40 | .74 | 0.19 | 10.1 | ||||
| RBM15-MKL1 | 93/367 | 1/2 | 1.76 | 0.57 | 0.24 | 12.7 | ||||
| MECOM overexpression | 71/312 | 23/57 | 1.91 | .007 | 1.20 | 3.07 | ||||
| KMT2A-PTD | 89/356 | 5/13 | 2.28 | .04 | 1.06 | 4.94 | ||||
| FLT3-ITD | 70/322 | 24/47 | 2.92 | <.001 | 1.83 | 4.65 | 2.53 | <.001 | 1.57 | 4.08 |
| CBFA2T3-GLIS2 | 87/358 | 7/11 | 3.00 | .005 | 2.54 | 6.48 | ||||
| PRDM16 overexpression | 52/285 | 42/84 | 3.09 | <.001 | 2.06 | 4.65 | ||||
| KMT2A-AFDN | 91/365 | 3/4 | 3.15 | .051 | 1.00 | 9.97 | ||||
| NUP98-KDM5A | 91/363 | 3/6 | 3.20 | .049 | 1.01 | 10.2 | ||||
| RUNX1 | 89/361 | 5/8 | 3.80 | .004 | 1.54 | 9.38 | ||||
| DEK-NUP214 | 91/365 | 3/4 | 4.91 | .007 | 1.39 | 15.6 | ||||
| NUP98-NSD1 | 85/358 | 9/11 | 5.07 | <.01 | 2.54 | 10.1 | ||||
| FUS-ERG | 89/364 | 5/5 | 6.80 | <.001 | 2.75 | 16.8 | 4.54 | <.001 | 1.81 | 11.4 |
| RPN1-MECOM | 92/367 | 2/2 | 7.84 | .04 | 1.92 | 32.0 | 5.44 | .02 | 1.32 | 22.4 |
| OS . | . | . | Univariate analysis . | Multivariate analysis . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of deaths/patients . | . | . | 95% CI . | . | . | 95% CI . | ||||
| Negative . | Positive . | HR . | P . | Lower . | Upper . | HR . | P . | Lower . | Upper . | |
| CBFB-MYH11 | 93/338 | 1/31 | 0.11 | .03 | 0.02 | 0.80 | 0.08 | .01 | 0.01 | 0.58 |
| Biallelic CEBPA | 93/346 | 1/23 | 0.16 | .07 | 0.02 | 1.13 | 0.10 | .02 | 0.01 | 0.69 |
| RUNX1-RUNX1T1 | 86/263 | 8/106 | 0.19 | <.001 | 0.09 | 0.39 | 0.17 | <.001 | 0.08 | 0.35 |
| NPM1 | 93/351 | 1/18 | 0.19 | .10 | 0.03 | 1.35 | 0.09 | .02 | 0.01 | 0.64 |
| KIT | 80/283 | 14/86 | 0.43 | .02 | 0.21 | 0.85 | ||||
| KMT2A rearrangement | 75/308 | 19/61 | 1.10 | .73 | 0.64 | 1.88 | ||||
| PICALM-MLLT10 | 93/366 | 1/3 | 1.22 | .84 | 0.17 | 8.78 | ||||
| WT1 | 86/345 | 8/24 | 1.33 | .44 | 0.64 | 2.74 | ||||
| KAT6A-CREBBP | 93/366 | 1/3 | 1.40 | .74 | 0.19 | 10.1 | ||||
| RBM15-MKL1 | 93/367 | 1/2 | 1.76 | 0.57 | 0.24 | 12.7 | ||||
| MECOM overexpression | 71/312 | 23/57 | 1.91 | .007 | 1.20 | 3.07 | ||||
| KMT2A-PTD | 89/356 | 5/13 | 2.28 | .04 | 1.06 | 4.94 | ||||
| FLT3-ITD | 70/322 | 24/47 | 2.92 | <.001 | 1.83 | 4.65 | 2.53 | <.001 | 1.57 | 4.08 |
| CBFA2T3-GLIS2 | 87/358 | 7/11 | 3.00 | .005 | 2.54 | 6.48 | ||||
| PRDM16 overexpression | 52/285 | 42/84 | 3.09 | <.001 | 2.06 | 4.65 | ||||
| KMT2A-AFDN | 91/365 | 3/4 | 3.15 | .051 | 1.00 | 9.97 | ||||
| NUP98-KDM5A | 91/363 | 3/6 | 3.20 | .049 | 1.01 | 10.2 | ||||
| RUNX1 | 89/361 | 5/8 | 3.80 | .004 | 1.54 | 9.38 | ||||
| DEK-NUP214 | 91/365 | 3/4 | 4.91 | .007 | 1.39 | 15.6 | ||||
| NUP98-NSD1 | 85/358 | 9/11 | 5.07 | <.01 | 2.54 | 10.1 | ||||
| FUS-ERG | 89/364 | 5/5 | 6.80 | <.001 | 2.75 | 16.8 | 4.54 | <.001 | 1.81 | 11.4 |
| RPN1-MECOM | 92/367 | 2/2 | 7.84 | .04 | 1.92 | 32.0 | 5.44 | .02 | 1.32 | 22.4 |
GVHD, graft-versus-host disease; TMA, thrombotic microangiopathy.